Novacyt (LON:NCYT) Releases Quarterly Earnings Results

Novacyt (LON:NCYT) announced its earnings results on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative net margin of 103.08% and a negative return on equity of 96.44%.

Novacyt Trading Down 2.1%

Shares of LON NCYT traded down GBX 0.90 during midday trading on Wednesday, hitting GBX 42. 60,649 shares of the company traded hands, compared to its average volume of 175,063. Novacyt has a 12-month low of GBX 26.60 and a 12-month high of GBX 86. The firm has a market cap of £30.45 million, a P/E ratio of -1.31 and a beta of 1.11. The stock has a 50-day moving average price of GBX 41.77 and a 200 day moving average price of GBX 39.06. The company has a debt-to-equity ratio of 44.74, a quick ratio of 4.46 and a current ratio of 4.74.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.